{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T02:55:22Z","timestamp":1793933722965,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T00:00:00Z","timestamp":1624233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The outcomes in systemic AL amyloidosis are dependent on the depth of haematologic response. However, there is limited data on the impact of the speed of response on outcomes. Here we report the impact of speed of response in a cohort of AL patients treated with upfront Bortezomib. Patients seen from February 2010 until August 2019 are included in the present analysis. 1194 &amp; 1133 patients comprised the ITT and 1-month landmark cohorts. In the landmark cohort, 137 (11.5%), 270 (22.6%), 252 (21.1%) and 352 (31.1%) patients had a CR, VGPR, PR and NR at 1-month. Patients with \u2265 VGPR at 1-month had significantly better survival (median not reached; at the end of 1, 2, 5,10 years, 87%\/92%, 83%\/87%, 68%\/72% and 63%\/58% of patients in CR\/VGPR, respectively, were alive) compared to those with a PR (median OS 60 months) or NR (median OS 32 months) (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.005). At 1-month, patients with CR and iFLC &lt; 20\u2009mg\/l had a significantly better survival compared to CR and iFLC &gt; 20\u2009mg\/l (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Reaching \u2265 VGPR at 1-month significantly improved survival in all Mayo disease stages. In conclusion, patients achieving an early deep haematologic response have a significantly superior survival irrespective of cardiac involvement.<\/jats:p>","DOI":"10.1038\/s41408-021-00510-7","type":"journal-article","created":{"date-parts":[[2021,6,21]],"date-time":"2021-06-21T18:04:51Z","timestamp":1624298691000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Impact of early response on outcomes in AL amyloidosis following treatment with frontline Bortezomib"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5650-0088","authenticated-orcid":false,"given":"Sriram","family":"Ravichandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver C.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9335-5526","authenticated-orcid":false,"given":"Steven","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Foard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Martinez-Naharro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian D.","family":"Gillmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen J.","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Sachchithanantham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shameem","family":"Mahmood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip N.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4406-7237","authenticated-orcid":false,"given":"Ashutosh D.","family":"Wechalekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,21]]},"reference":[{"key":"510_CR1","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","volume":"22","author":"A Dispenzieri","year":"2004","unstructured":"Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal Pro-Brain natriuretic peptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 2004;22:3751\u20137.","journal-title":"J. Clin. Oncol."},{"key":"510_CR2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1056\/NEJMc1917321","volume":"382","author":"S Ravichandran","year":"2020","unstructured":"Ravichandran S, Lachmann HJ, Wechalekar AD. Epidemiologic and survival trends in amyloidosis, 1987\u20132019. N. Engl. J. Med. 2020;382:1567\u20138.","journal-title":"N. Engl. J. Med"},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 2012;30:4541\u20139.","journal-title":"J. Clin. Oncol."},{"key":"510_CR4","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1182\/blood.2019000834","volume":"134","author":"R Manwani","year":"2019","unstructured":"Manwani R, Cohen O, Sharpley F, Mahmood S, Sachchithanantham S, Foard D, et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. Blood. 2019;134:2271\u201380.","journal-title":"Blood."},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1182\/blood-2019-127004","volume":"134","author":"A Godara","year":"2019","unstructured":"Godara A, Toskic D, Rosenthal B, Varga C, Kugelmass A, Zhou P, et al. In systemic light-chain amyloidosis complete and very good partial responses are not enough: involved free light chain (iFLC) Levels < 10mg\/L are associated with optimal long-term survival. Blood. 2019;134:4369.","journal-title":"Blood."},{"key":"510_CR6","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.3324\/haematol.2017.178095","volume":"103","author":"R Manwani","year":"2018","unstructured":"Manwani R, Foard D, Mahmood S, Sachchithanantham S, Lane T, Quarta C, et al. Rapid hematologic responses improve outcomes in patients with very advanced (stage IIIb) cardiac immunoglobulin light chain amyloidosis. Haematologica. 2018;103:e165\u2013e8.","journal-title":"Haematologica."},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.kint.2017.05.004","volume":"92","author":"T Rezk","year":"2017","unstructured":"Rezk T, Lachmann HJ, Fontana M, Sachchithanantham S, Mahmood S, Petrie A, et al. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. Kidney Int. 2017;92:1476\u201383.","journal-title":"Kidney Int."},{"key":"510_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2017-02-767475","volume":"130","author":"T Dittrich","year":"2017","unstructured":"Dittrich T, Bochtler T, Kimmich C, Becker N, Jauch A, Goldschmidt H, et al. AL amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis. Blood. 2017;130:632\u201342.","journal-title":"Blood."},{"key":"510_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/blood-2017-02-767467","volume":"130","author":"P Milani","year":"2017","unstructured":"Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G. Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood. 2017;130:625\u201331.","journal-title":"Blood."},{"key":"510_CR10","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/leu.2012.100","volume":"26","author":"RL Comenzo","year":"2012","unstructured":"Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012;26:2317\u201325.","journal-title":"Leukemia."},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J. Hematol. 2005;79:319\u201328.","journal-title":"Am J. Hematol."},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1182\/blood-2012-12-473066","volume":"121","author":"AD Wechalekar","year":"2013","unstructured":"Wechalekar AD, Schonland SO, Kastritis E, Gillmore JD, Dimopoulos MA, Lane T, et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013;121:3420\u20137.","journal-title":"Blood."},{"key":"510_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2020.1868810","volume":"28","author":"G Palladini","year":"2021","unstructured":"Palladini G, Sch\u00f6nland SO, Sanchorawala V, Kumar S, Wechalekar A, Hegenbart U, et al. Clarification on the definition of complete haematologic response in light-chain (AL) amyloidosis. Amyloid. 2021;28:1\u20132.","journal-title":"Amyloid."},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1182\/bloodadvances.2018022806","volume":"3","author":"N Tandon","year":"2019","unstructured":"Tandon N, Sidana S, Rajkumar SV, Gertz MA, Buadi FK, Lacy MQ, et al. Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma. Blood Adv. 2019;3:744\u201350.","journal-title":"Blood Adv."},{"key":"510_CR15","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","volume":"110","author":"F van Rhee","year":"2007","unstructured":"van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110:827\u201332.","journal-title":"Blood."},{"key":"510_CR16","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1182\/bloodadvances.2019000432","volume":"3","author":"Y Yan","year":"2019","unstructured":"Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, et al. The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019;3:2895\u2013904.","journal-title":"Blood Adv."},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.1989.7.1.119","volume":"7","author":"M Boccadoro","year":"1989","unstructured":"Boccadoro M, Marmont F, Tribalto M, Fossati G, Redoglia V, Battaglio S, et al. Early responder myeloma: kinetic studies identify a patient subgroup characterised by very poor prognosis. J. Clin. Oncol. 1989;7:119\u201325.","journal-title":"J. Clin. Oncol."},{"key":"510_CR18","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2015-10-676361","volume":"128","author":"T Bochtler","year":"2016","unstructured":"Bochtler T, Hegenbart U, Kunz C, Benner A, Kimmich C, Seckinger A, et al. Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood. 2016;128:594\u2013602.","journal-title":"Blood."},{"key":"510_CR19","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International staging system for multiple myeloma. J. Clin. Oncol. 2005;23:3412\u201320.","journal-title":"J. Clin. Oncol."},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2020.1798224","volume":"28","author":"E Kastritis","year":"2020","unstructured":"Kastritis E, Fotiou D, Theodorakakou F, Dialoupi I, Migkou M, Roussou M. et al. Timing and impact of a deep response in the outcome of patients with systemic light chain (AL) amyloidosis. Amyloid. 2020;28:3\u201311.","journal-title":"Amyloid"},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2019-130378","volume":"134","author":"P Milani","year":"2019","unstructured":"Milani P, Basset M, Foli A, Nuvolone M, Ripepi J, Bozzola M, et al. The quest for indicators of profound hematologic response in AL amyloidosis: complete response remains the optimal goal of therapy. Blood. 2019;134:1901.","journal-title":"Blood."},{"key":"510_CR22","doi-asserted-by":"crossref","unstructured":"Efstathios Kastritis GP, Monique C Minnema, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) in patients with newly diagnosed light chains (AL) amyloidosis: primary results from the phase 3 ANDROMEDA study. EHA 25 Virtual2020.","DOI":"10.1200\/JCO.2021.39.15_suppl.8003"},{"key":"510_CR23","doi-asserted-by":"crossref","unstructured":"Palladini G, Kastritis E, Maurer MS, Zonder JA, Minnema Mc, Wechalekar AD, et al. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020;136:71\u201380.","DOI":"10.1182\/blood.2019004460"},{"key":"510_CR24","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/bjh.13155","volume":"168","author":"AD Wechalekar","year":"2015","unstructured":"Wechalekar AD, Gillmore JD, Bird J, Cavenagh J, Hawkins S, Kazmi M, et al. Guidelines on the management of AL amyloidosis. Br J. Haematol. 2015;168:186\u2013206.","journal-title":"Br J. Haematol."},{"key":"510_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/blood-2006-07-035352","volume":"109","author":"AD Wechalekar","year":"2006","unstructured":"Wechalekar AD, Goodman HJB, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood. 2006;109:457\u201364.","journal-title":"Blood."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00510-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00510-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:46:28Z","timestamp":1669909588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00510-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,21]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00510-7","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,21]]},"assertion":[{"value":"14 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.W. has received honoraria from Janssen, GSK, Celgene, and Takeda. The other authors do not have any conflict of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}